Rituximab vs Rituximab-abbs (Truxima)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline

Rituximab · Rituxan

Marketed by Roche and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT00468546 · Phase 3 · completed

The REFLEX phase 3 trial: randomized, double-blind, placebo-controlled, 520 participants with rheumatoid arthritis who had failed anti-TNF therapy, all on background methotrexate. The primary endpoint, ACR20 response at week 24, was reached by 153 of 298 participants on rituximab (51.3%) versus 36 of 201 on placebo (17.9%). ClinicalTrials.gov records no statistical analysis for the comparison, but a 33-percentage-point difference on a validated clinical response endpoint at this sample size is arithmetically undeniable, so the primary is read as met (significance inferred from counts).

Next expected readout: July 2027 · NCT06581562 (registry estimate)

Reported efficacy

Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3% (met)

Result source: NCT00299130

Rituximab-abbs (Truxima)

Marketed by Celltrion and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02149121 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial with an adequately sized population (384 enrolled) that pre-specified formal equivalence margins for both its pharmacokinetic and its clinical disease-activity (DAS28-CRP) primary endpoints, and every comparison landed entirely within the required margin, meaning the biosimilar demonstrated therapeutic equivalence to the reference product on a validated hard clinical measure of rheumatoid arthritis activity, not just a proxy lab value.

Reported efficacy

Analysis of Serum AUC0-last of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA); Analysis of Serum AUC0-inf of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Serum Cmax of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Change From Baseline of DAS28 (CRP) at Week 24 (ANCOVA) (at Week 24 of the Main Study Period): Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%). (met)

Result source: NCT02149121

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointRituximabRituximab-abbs (Truxima)
ACR2050.6% vs 23.3%+27.3 vs placebo2 x 1.0 g · wk 24 · n 170NCT00299130
5 other results
  • 54.5% vs 23.3% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · primary NCT00299130
  • 53.5% vs 44.6% wk 48 · n 318 · Phase 3 · primary NCT00266227
  • 51.3% vs 17.9% wk 24 · n 298 · Phase 3 · primary NCT00468546
  • 80% vs 64.3% 1.0 g x 2 · wk 52 · n 250 · Phase 3 · secondary NCT00299104
  • 76.7% vs 64.3% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
—Not reported
ACR5064.8% vs 41.8%+23 vs placebo1.0 g x 2 · wk 52 · n 250NCT00299104
6 other results
  • 34.1% vs 18.6% 2 x 1.0 g · wk 48 · n 170 · Phase 3 · secondary NCT00299130
  • 25.9% vs 9.3% 2 x 1.0 g · wk 24 · n 170 · Phase 3 · secondary NCT00299130
  • 59.4% vs 41.8% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • 32.9% vs 18.6% 2 x 0.5 g · wk 48 · n 167 · Phase 3 · secondary NCT00299130
  • 26.3% vs 9.3% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · secondary NCT00299130
  • 26.8% vs 5.5% wk 24 · n 298 · Phase 3 · secondary NCT00468546
—Not reported
ACR7046.8% vs 24.9%+21.9 vs placebo1.0 g x 2 · wk 52 · n 250NCT00299104
6 other results
  • 13.5% vs 9.3% 2 x 1.0 g · wk 48 · n 170 · Phase 3 · secondary NCT00299130
  • 10% vs 5.2% 2 x 1.0 g · wk 24 · n 170 · Phase 3 · secondary NCT00299130
  • 42.2% vs 24.9% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • 12.6% vs 9.3% 2 x 0.5 g · wk 48 · n 167 · Phase 3 · secondary NCT00299130
  • 9% vs 5.2% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · secondary NCT00299130
  • 12.4% vs 1.5% wk 24 · n 298 · Phase 3 · secondary NCT00468546
—Not reported
DAS28-CRP remission—Not posted · NCT00578305—Not reported
HAQ-DI, change-1.1 vs -0.8−0.2 vs placebo1.0 g x 2 · wk 104 · n 248NCT00299104
9 other results
  • -1.0 vs -0.8 1.0 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • -1038 vs -0.8 0.5 g x 2 · wk 104 · n 247 · Phase 3 · secondary NCT00299104
  • -1.0 vs -0.8 0.5 g x 2 · wk 52 · n 247 · Phase 3 · secondary NCT00299104
  • -0.3 vs -0.2 wk 48 · n 316 · Phase 3 · secondary NCT00266227
  • -0.4 vs -0.2 1000 mg · wk 52 · n 60 · Phase 3 · secondary NCT00578305
  • -0.4 vs -0.2 1000 mg · wk 24 · n 60 · Phase 3 · secondary NCT00578305
  • -0.5 vs -0.2 500 mg · wk 52 · n 62 · Phase 3 · secondary NCT00578305
  • -0.4 vs -0.2 500 mg · wk 24 · n 62 · Phase 3 · secondary NCT00578305
  • -0.5 vs -0.4 wk 260 · n 100 · Phase 3 · secondary NCT02097745
—Not reported
Modified Sharp score, change0.4 vs 1.1−0.7 vs placebo1.0 g x 2 · wk 52 · n 244NCT00299104
6 other results
  • 0.6 vs 1.1 0.5 g x 2 · wk 52 · n 239 · Phase 3 · primary NCT00299104
  • 0.4 vs 1.9 1.0 g x 2 · wk 104 · n 243 · Phase 3 · secondary NCT00299104
  • 0.3 vs 0.7 1.0 g x 2 · wk 24 · n 242 · Phase 3 · secondary NCT00299104
  • 0.8 vs 1.9 0.5 g x 2 · wk 104 · n 238 · Phase 3 · secondary NCT00299104
  • 0.5 vs 0.7 0.5 g x 2 · wk 24 · n 238 · Phase 3 · secondary NCT00299104
  • 3.2 vs 5.4 wk 260 · n 105 · Phase 3 · secondary NCT02097745
—Not reported

ACR20

Rituximab
50.6% vs 23.3%+27.3 vs placebo2 x 1.0 g · wk 24 · n 170NCT00299130
5 other results
  • 54.5% vs 23.3% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · primary NCT00299130
  • 53.5% vs 44.6% wk 48 · n 318 · Phase 3 · primary NCT00266227
  • 51.3% vs 17.9% wk 24 · n 298 · Phase 3 · primary NCT00468546
  • 80% vs 64.3% 1.0 g x 2 · wk 52 · n 250 · Phase 3 · secondary NCT00299104
  • 76.7% vs 64.3% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
Rituximab-abbs (Truxima)
—Not reported

ACR50

Rituximab
64.8% vs 41.8%+23 vs placebo1.0 g x 2 · wk 52 · n 250NCT00299104
6 other results
  • 34.1% vs 18.6% 2 x 1.0 g · wk 48 · n 170 · Phase 3 · secondary NCT00299130
  • 25.9% vs 9.3% 2 x 1.0 g · wk 24 · n 170 · Phase 3 · secondary NCT00299130
  • 59.4% vs 41.8% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • 32.9% vs 18.6% 2 x 0.5 g · wk 48 · n 167 · Phase 3 · secondary NCT00299130
  • 26.3% vs 9.3% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · secondary NCT00299130
  • 26.8% vs 5.5% wk 24 · n 298 · Phase 3 · secondary NCT00468546
Rituximab-abbs (Truxima)
—Not reported

ACR70

Rituximab
46.8% vs 24.9%+21.9 vs placebo1.0 g x 2 · wk 52 · n 250NCT00299104
6 other results
  • 13.5% vs 9.3% 2 x 1.0 g · wk 48 · n 170 · Phase 3 · secondary NCT00299130
  • 10% vs 5.2% 2 x 1.0 g · wk 24 · n 170 · Phase 3 · secondary NCT00299130
  • 42.2% vs 24.9% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • 12.6% vs 9.3% 2 x 0.5 g · wk 48 · n 167 · Phase 3 · secondary NCT00299130
  • 9% vs 5.2% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · secondary NCT00299130
  • 12.4% vs 1.5% wk 24 · n 298 · Phase 3 · secondary NCT00468546
Rituximab-abbs (Truxima)
—Not reported

DAS28-CRP remission

Rituximab
—Not posted · NCT00578305
Rituximab-abbs (Truxima)
—Not reported

HAQ-DI, change

Rituximab
-1.1 vs -0.8−0.2 vs placebo1.0 g x 2 · wk 104 · n 248NCT00299104
9 other results
  • -1.0 vs -0.8 1.0 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • -1038 vs -0.8 0.5 g x 2 · wk 104 · n 247 · Phase 3 · secondary NCT00299104
  • -1.0 vs -0.8 0.5 g x 2 · wk 52 · n 247 · Phase 3 · secondary NCT00299104
  • -0.3 vs -0.2 wk 48 · n 316 · Phase 3 · secondary NCT00266227
  • -0.4 vs -0.2 1000 mg · wk 52 · n 60 · Phase 3 · secondary NCT00578305
  • -0.4 vs -0.2 1000 mg · wk 24 · n 60 · Phase 3 · secondary NCT00578305
  • -0.5 vs -0.2 500 mg · wk 52 · n 62 · Phase 3 · secondary NCT00578305
  • -0.4 vs -0.2 500 mg · wk 24 · n 62 · Phase 3 · secondary NCT00578305
  • -0.5 vs -0.4 wk 260 · n 100 · Phase 3 · secondary NCT02097745
Rituximab-abbs (Truxima)
—Not reported

Modified Sharp score, change

Rituximab
0.4 vs 1.1−0.7 vs placebo1.0 g x 2 · wk 52 · n 244NCT00299104
6 other results
  • 0.6 vs 1.1 0.5 g x 2 · wk 52 · n 239 · Phase 3 · primary NCT00299104
  • 0.4 vs 1.9 1.0 g x 2 · wk 104 · n 243 · Phase 3 · secondary NCT00299104
  • 0.3 vs 0.7 1.0 g x 2 · wk 24 · n 242 · Phase 3 · secondary NCT00299104
  • 0.8 vs 1.9 0.5 g x 2 · wk 104 · n 238 · Phase 3 · secondary NCT00299104
  • 0.5 vs 0.7 0.5 g x 2 · wk 24 · n 238 · Phase 3 · secondary NCT00299104
  • 3.2 vs 5.4 wk 260 · n 105 · Phase 3 · secondary NCT02097745
Rituximab-abbs (Truxima)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Rituximab: 6 of 6 rows · Rituximab-abbs (Truxima): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRituximabRituximab-abbs (Truxima)
DAS28-CRP
absolute change · score
-1.8 vs -1.5 placebo score @ 48wka,b
NCT00266227 · Phase 3
-2.7 vs -2.6 Rituxan score @ 48wka,b
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
DAS28-ESR
absolute change · score
-2.1 vs -1.8 placebo score @ 48wka,b
NCT00266227 · Phase 3
-2.9 vs -2.8 Rituxan score @ 48wka,b
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Dropout rate
17.9%c
NCT00468546 · Phase 3 · combination
show 48 more results
—
NCT00266227 · Phase 3
68.3%1.0 g x 2
NCT00299104 · Phase 3 · combination
69.4%0.5 g x 2
NCT00299104 · Phase 3 · combination
—1.0 g
NCT00299130 · Phase 3 · combination
29.2%2 x 1.0 g
NCT00299130 · Phase 3 · combination
25.6%2 x 0.5 g
NCT00299130 · Phase 3 · combination
20.8%
NCT01382940 · Phase 4 · registry result, not featured evidence
33.3%
NCT01000610 · Phase 4 · registry result, not featured evidence
—1000 mg
NCT00934648 · Phase 4 · registry result, not featured evidence
—
NCT00502853 · Phase 4 · registry result, not featured evidence · combination
—
NCT00504777 · Phase 4 · registry result, not featured evidence · combination
—1000 mg
NCT00424502 · Phase 4 · registry result, not featured evidence
7.5%
NCT00462345 · Phase 4 · registry result, not featured evidence · combination
53.1%
NCT02097745 · Phase 3 · registry result, not featured evidence
25.1%
NCT00503425 · Phase 3 · registry result, not featured evidence
6.7%1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
4.8%500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
12%Decreased Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
11.7%Escalated Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
4.3%High Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
—Low Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
23.7%1000 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
33%500 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
32.1%1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
16.4%1000 mg x 2
NCT01126541 · Phase 3 · registry result, not featured evidence
—
NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy
30%
NCT00578565 · Phase 3 · registry result, not featured evidence
—
NCT02079532 · Phase 3 · registry result, not featured evidence · combination
—Initial Treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
—Re-treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
19%
NCT00502996 · Phase 3 · registry result, not featured evidence
—
NCT02006706 · Phase 3 · registry result, not featured evidence · combination
41.5%
NCT02093026 · Phase 2 · registry result, not featured evidence
5.8%Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
—Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00147966 · Phase 2 · registry result, not featured evidence
52.4%1000 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
47.6%500 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
—Rituximab-EU: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—Rituximab-US: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
0%
NCT00844714 · Phase na · registry result, not featured evidence
13%CT-P10 (Main Study Period)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
—CT-P10/CT-P10 (Extension Study Per
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Discontinued due to AEs
2.6%c
NCT00468546 · Phase 3 · combination
show 48 more results
—
NCT00266227 · Phase 3
2.8%1.0 g x 2
NCT00299104 · Phase 3 · combination
3.6%0.5 g x 2
NCT00299104 · Phase 3 · combination
—1.0 g
NCT00299130 · Phase 3 · combination
7.6%2 x 1.0 g
NCT00299130 · Phase 3 · combination
4.8%2 x 0.5 g
NCT00299130 · Phase 3 · combination
5.4%
NCT01382940 · Phase 4 · registry result, not featured evidence
5.6%
NCT01000610 · Phase 4 · registry result, not featured evidence
—1000 mg
NCT00934648 · Phase 4 · registry result, not featured evidence
—
NCT00502853 · Phase 4 · registry result, not featured evidence · combination
—
NCT00504777 · Phase 4 · registry result, not featured evidence · combination
—1000 mg
NCT00424502 · Phase 4 · registry result, not featured evidence
—
NCT00462345 · Phase 4 · registry result, not featured evidence · combination
7.5%
NCT02097745 · Phase 3 · registry result, not featured evidence
2.3%
NCT00503425 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
0%Decreased Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
2.5%Escalated Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
1.1%High Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
—Low Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
1.2%1000 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
3.4%500 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
4.9%1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
2.7%1000 mg x 2
NCT01126541 · Phase 3 · registry result, not featured evidence
—
NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy
30%
NCT00578565 · Phase 3 · registry result, not featured evidence
—
NCT02079532 · Phase 3 · registry result, not featured evidence · combination
—Initial Treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
—Re-treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
0.9%
NCT00502996 · Phase 3 · registry result, not featured evidence
—
NCT02006706 · Phase 3 · registry result, not featured evidence · combination
5.6%
NCT02093026 · Phase 2 · registry result, not featured evidence
0%Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
—Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
—
NCT00147966 · Phase 2 · registry result, not featured evidence
9.5%1000 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
19%500 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
—Rituximab-EU: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—Rituximab-US: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—
NCT00844714 · Phase na · registry result, not featured evidence
1.2%CT-P10 (Main Study Period)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
—CT-P10/CT-P10 (Extension Study Per
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Serious AEs
16.2%c
NCT00468546 · Phase 3 · combination
show 48 more results
13.1%
NCT00266227 · Phase 3
22.1%1.0 g x 2
NCT00299104 · Phase 3 · combination
15.5%0.5 g x 2
NCT00299104 · Phase 3 · combination
27.1%1.0 g
NCT00299130 · Phase 3 · combination
—2 x 1.0 g
NCT00299130 · Phase 3 · combination
31.1%2 x 0.5 g
NCT00299130 · Phase 3 · combination
8.5%
NCT01382940 · Phase 4 · registry result, not featured evidence
33.3%
NCT01000610 · Phase 4 · registry result, not featured evidence
0%1000 mg
NCT00934648 · Phase 4 · registry result, not featured evidence
20%
NCT00502853 · Phase 4 · registry result, not featured evidence · combination
8.3%
NCT00504777 · Phase 4 · registry result, not featured evidence · combination
0%1000 mg
NCT00424502 · Phase 4 · registry result, not featured evidence
15%
NCT00462345 · Phase 4 · registry result, not featured evidence · combination
58.8%
NCT02097745 · Phase 3 · registry result, not featured evidence
33.5%
NCT00503425 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
6.7%1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
10.6%1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
1.9%1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
4.8%500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
6%500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
0%500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
12%Decreased Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
17.6%Escalated Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
17.2%High Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
11.2%Low Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
12%1000 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
15.3%500 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
19.8%1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
28.8%1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
36.8%1000 mg x 2
NCT01126541 · Phase 3 · registry result, not featured evidence
24.4%
NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy
20%
NCT00578565 · Phase 3 · registry result, not featured evidence
11.9%
NCT02079532 · Phase 3 · registry result, not featured evidence · combination
10%Initial Treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
9.1%Re-treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
5.2%
NCT00502996 · Phase 3 · registry result, not featured evidence
14.3%
NCT02006706 · Phase 3 · registry result, not featured evidence · combination
49.5%
NCT02093026 · Phase 2 · registry result, not featured evidence
—Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
4.4%Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
8.3%
NCT00147966 · Phase 2 · registry result, not featured evidence
10%1000 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
14.3%500 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
6.3%Rituximab-EU: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
3.3%Rituximab-US: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
0%
NCT00844714 · Phase na · registry result, not featured evidence
8.1%CT-P10 (Main Study Period)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
3.3%CT-P10/CT-P10 (Extension Study Per
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Most frequent reported AEs
c
rheumatoid arthritis 34.4% (placebo 41.8%)
upper respiratory tract infection 11.7% (placebo 8.2%)
headache 10.1% (placebo 10.1%)
NCT00468546 · Phase 3 · combination
show 42 more results
rheumatoid arthritis 23.1% (placebo 38.1%)
upper respiratory tract infection 22.2% (placebo 20.6%)
headache 15.9% (placebo 11.6%)
NCT00266227 · Phase 3
1.0 g x 2
infusion related reaction 25.5% (placebo 21.3%)
upper respiratory tract infection 22.1% (placebo 17.7%)
nasopharyngitis 19.8% (placebo 17.3%)
NCT00299104 · Phase 3 · combination
0.5 g x 2
infusion related reaction 19.8% (placebo 21.3%)
upper respiratory tract infection 17% (placebo 17.7%)
nasopharyngitis 15.2% (placebo 17.3%)
NCT00299104 · Phase 3 · combination
1.0 g
infusion related reaction 34.7% (placebo 19.2%)
upper respiratory tract infection 29.4% (placebo 7.6%)
nasopharyngitis 24.7% (placebo 9.9%)
NCT00299130 · Phase 3 · combination
2 x 0.5 g
infusion related reaction 35.3% (placebo 19.2%)
upper respiratory tract infection 35.3% (placebo 7.6%)
rheumatoid arthritis 29.3% (placebo 17.4%)
NCT00299130 · Phase 3 · combination
headache 5.7%
upper respiratory tract infection 5.4%
NCT01382940 · Phase 4 · registry result, not featured evidence
hypertension 11.1%
blurred vision 5.6%
dyspnea stage 2 5.6%
NCT01000610 · Phase 4 · registry result, not featured evidence
1000 mg
difficulty breathing 6.7%
diffuse skin rash 6.7%
dyspnea 6.7%
NCT00934648 · Phase 4 · registry result, not featured evidence
influenza 30%
pharyngitis 30%
alanine aminotransferase increased 20%
NCT00502853 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 22.2%
cough 13.9%
dizziness 5.6%
NCT00504777 · Phase 4 · registry result, not featured evidence · combination
1000 mg
fever 10%
throat pain 10%
upper respiratory tract infection 10%
NCT00424502 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 30%
rash 15%
arthralgia 12.5%
NCT00462345 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 64.8% (placebo 40.7%)
infusion related reaction 46.3% (placebo 18.6%)
upper respiratory tract infection 39.4% (placebo 10%)
NCT02097745 · Phase 3 · registry result, not featured evidence
back pain 13.4%
rheumatoid arthritis 12%
vitamin d deficiency 10.5%
NCT00503425 · Phase 3 · registry result, not featured evidence
1000 mg
bronchitis 8.3% (placebo 3.2%)
back pain 6.7% (placebo 1.6%)
upper respiratory tract infection 6.7% (placebo 1.6%)
NCT00578305 · Phase 3 · registry result, not featured evidence
1000 mg
arthralgia 0% (placebo 1.6%)
back pain 0% (placebo 1.6%)
bronchitis 0% (placebo 3.2%)
NCT00578305 · Phase 3 · registry result, not featured evidence
1000 mg
arthralgia 0% (placebo 1.6%)
back pain 0% (placebo 1.6%)
bronchitis 0% (placebo 3.2%)
NCT00578305 · Phase 3 · registry result, not featured evidence
500 mg
arthralgia 6.5% (placebo 1.6%)
bronchitis 6.5% (placebo 3.2%)
headache 6.5% (placebo 1.6%)
NCT00578305 · Phase 3 · registry result, not featured evidence
500 mg
arthralgia 0% (placebo 1.6%)
back pain 0% (placebo 1.6%)
bronchitis 0% (placebo 3.2%)
NCT00578305 · Phase 3 · registry result, not featured evidence
500 mg
arthralgia 0% (placebo 1.6%)
back pain 0% (placebo 1.6%)
bronchitis 0% (placebo 3.2%)
NCT00578305 · Phase 3 · registry result, not featured evidence
Decreased Dose
infusion related reaction 36%
nasopharyngitis 28%
rheumatoid arthritis 28%
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
Escalated Dose
infusion related reaction 37.8%
upper respiratory tract infection 31.1%
rheumatoid arthritis 27.7%
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
High Dose
infusion related reaction 38.7%
rheumatoid arthritis 32.3%
upper respiratory tract infection 30.1%
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
Low Dose
infusion related reaction 43.3%
rheumatoid arthritis 32.1%
upper respiratory tract infection 29.1%
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
1000 mg
upper respiratory tract infection 12.7%
rheumatoid arthritis 12.5%
arthralgia 11.7%
NCT00443651 · Phase 3 · registry result, not featured evidence
500 mg
rheumatoid arthritis 15.9%
upper respiratory tract infection 15.3%
headache 14.2%
NCT00443651 · Phase 3 · registry result, not featured evidence
1000 mg
urinary tract infection 17.3%
bronchitis 13.6%
headache 12.3%
NCT01126541 · Phase 3 · registry result, not featured evidence
1000 mg
bronchitis 19.7%
asthenia 16.7%
cough 16.7%
NCT01126541 · Phase 3 · registry result, not featured evidence
1000 mg x 2
bronchitis 23.5%
rheumatoid arthritis 17.6%
urinary tract infection 17.6%
NCT01126541 · Phase 3 · registry result, not featured evidence
nasopharyngitis 22.3%
bronchitis 8.8%
upper respiratory tract infection 6.2%
NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy
infusion reaction 10%
NCT00578565 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.3%
cough 6.3%
hypertension 5.6%
NCT02079532 · Phase 3 · registry result, not featured evidence · combination
rheumatoid arthritis 16.7%
nausea 14.2%
headache 11.7%
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
nausea 11.7%
nasopharyngitis 10.4%
headache 7.8%
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
headache 17.2%
urinary tract infection 9.9%
nausea 9.5%
NCT00502996 · Phase 3 · registry result, not featured evidence
rheumatoid arthritis 50.8% (placebo 42.5%)
infusion related reaction 43.7% (placebo 19.7%)
upper respiratory tract infection 32.9% (placebo 5.5%)
NCT02093026 · Phase 2 · registry result, not featured evidence
rheumatoid arthritis 17.6%
headache 13.2%
pruritus 13.2%
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
allergic reaction to detergent on hand and arm 4.2%
anemia 4.2%
contact dimities 4.2%
NCT00147966 · Phase 2 · registry result, not featured evidence
1000 mg
upper respiratory tract infection 35%
cough 15%
insomnia 15%
NCT00243412 · Phase 2 · registry result, not featured evidence
500 mg
sinusitis 28.6%
arthralgia 23.8%
nausea 23.8%
NCT00243412 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 9.4%
bronchitis 3.1%
fall 3.1%
NCT01643928 · Phase na · registry result, not featured evidence
arthralgia 10%
asthenia 6.7%
back pain 6.7%
NCT01643928 · Phase na · registry result, not featured evidence
infusion-related reaction 20.5%
upper respiratory tract infection 14.9%
urinary tract infection 9.3%
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
upper respiratory tract infection 8.2%
urinary tract infection 6.6%
infusion-related reaction 3.3%
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Rituximab

ACR20 80% (n=250) vs 64.3% (n=249) placebo @ 52wk1.0 g x 2
responder rate · % of participants
NCT00299104 · Phase 3 · combination
show 5 more results
50.6% (n=170) vs 23.3% (n=172) placebo @ 24wk2 x 1.0 g
NCT00299130 · Phase 3 · combination
76.7% (n=249) vs 64.3% (n=249) placebo @ 52wk0.5 g x 2
NCT00299104 · Phase 3 · combination
54.5% (n=167) vs 23.3% (n=172) placebo @ 24wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
51.3% (n=298) vs 17.9% (n=201) placebo @ 24wk*
NCT00468546 · Phase 3 · combination · converted to % from 153 participants as posted
53.5% (n=318) vs 44.6% (n=157) placebo @ 48wk*
NCT00266227 · Phase 3 · converted to % from 170 Participants as posted
ACR50 64.8% (n=250) vs 41.8% (n=249) placebo @ 52wk1.0 g x 2
responder rate · % of participants
NCT00299104 · Phase 3 · combination
show 6 more results
25.9% (n=170) vs 9.3% (n=172) placebo @ 24wk2 x 1.0 g
NCT00299130 · Phase 3 · combination
34.1% (n=170) vs 18.6% (n=172) placebo @ 48wk2 x 1.0 g
NCT00299130 · Phase 3 · combination
59.4% (n=249) vs 41.8% (n=249) placebo @ 52wk0.5 g x 2
NCT00299104 · Phase 3 · combination
26.3% (n=167) vs 9.3% (n=172) placebo @ 24wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
32.9% (n=167) vs 18.6% (n=172) placebo @ 48wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
26.8% (n=298) vs 5.5% (n=201) placebo @ 24wk*
NCT00468546 · Phase 3 · combination · converted to % from 80 participants as posted
ACR70 46.8% (n=250) vs 24.9% (n=249) placebo @ 52wk1.0 g x 2
responder rate · % of participants
NCT00299104 · Phase 3 · combination
show 6 more results
10% (n=170) vs 5.2% (n=172) placebo @ 24wk2 x 1.0 g
NCT00299130 · Phase 3 · combination
13.5% (n=170) vs 9.3% (n=172) placebo @ 48wk2 x 1.0 g
NCT00299130 · Phase 3 · combination
42.2% (n=249) vs 24.9% (n=249) placebo @ 52wk0.5 g x 2
NCT00299104 · Phase 3 · combination
9% (n=167) vs 5.2% (n=172) placebo @ 24wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
12.6% (n=167) vs 9.3% (n=172) placebo @ 48wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
12.4% (n=298) vs 1.5% (n=201) placebo @ 24wk*
NCT00468546 · Phase 3 · combination · converted to % from 37 participants as posted
DAS28 Low Disease Activity 12.4% (n=170) vs 4.7% (n=172) placebo @ 24wk2 x 1.0 g
responder rate · % of participants
Low disease activity
NCT00299130 · Phase 3 · combination
show 4 more results
24.3% (n=169) vs 18.1% (n=171) placebo @ 48wk2 x 1.0 g
Low Disease Activity
NCT00299130 · Phase 3 · combination
17.5% (n=166) vs 4.7% (n=172) placebo @ 24wk2 x 0.5 g
Low Disease Activity
NCT00299130 · Phase 3 · combination
20% (n=165) vs 18.1% (n=171) placebo @ 48wk2 x 0.5 g
Low Disease Activity
NCT00299130 · Phase 3 · combination
15% (n=298) vs 2% (n=201) placebo @ 24wk
Low disease activity
NCT00468546 · Phase 3 · combination
DAS28-ESR Remission 9% (n=298) vs 0% (n=201) placebo @ 24wk
responder rate · % of participants
Remission
NCT00468546 · Phase 3 · combination
EULAR Moderate 50% (n=298) vs 19.9% (n=201) placebo @ 24wk
responder rate · % of participants
Moderate response
NCT00468546 · Phase 3 · combination · converted to % from 149 participants as posted
show 1 more result
47.5% (n=318) vs 42.7% (n=157) placebo @ 48wk
Moderate Response
NCT00266227 · Phase 3
EULAR Good 20.6% (n=170) vs 16.9% (n=172) placebo @ 48wk2 x 1.0 g
responder rate · % of participants
Good response
NCT00299130 · Phase 3 · combination
show 3 more results
19.8% (n=167) vs 16.9% (n=172) placebo @ 48wk2 x 0.5 g
Good Response
NCT00299130 · Phase 3 · combination
14.8% (n=298) vs 2% (n=201) placebo @ 24wk*
Good response
NCT00468546 · Phase 3 · combination · converted to % from 44 participants as posted
20.8% (n=318) vs 18.5% (n=157) placebo @ 48wk
Good Response
NCT00266227 · Phase 3
SF-36 Physical Component Summary 5.8 vs 0.9 placebo score @ 24wk
absolute change · score
Physical score
NCT00468546 · Phase 3 · combination
ACR50 28.9% (n=318) vs 26.1% (n=157) placebo @ 48wk
responder rate · % of participants
ACR50
NCT00266227 · Phase 3 · converted to % from 92 Participants as posted
ACR70 13.8% (n=318) vs 13.4% (n=157) placebo @ 48wk
responder rate · % of participants
ACR70
NCT00266227 · Phase 3 · converted to % from 44 Participants as posted
Swollen Joint Count -12.5 vs -10.2 placebo count @ 48wk
absolute change · count
NCT00266227 · Phase 3
Tender Joint Count -15.3 vs -14.7 placebo count @ 48wk
absolute change · count
NCT00266227 · Phase 3

+ 303 further endpoints in the CSV export.

Rituximab-abbs (Truxima)

DAS28-CRP -3 vs -3 Rituxan score @ 24wk
absolute change · score
Extension (open-label)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
DAS28-ESR -3.3 vs -3.3 Rituxan score @ 24wk
absolute change · score
Extension (open-label)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rituximab's landscape · Rituximab-abbs (Truxima)'s landscape